Pa Seputembara 27, tsamba lovomerezeka la CDE lidawonetsa kuti kugwiritsa ntchito chizindikiro chatsopano cha zonona za Pfize Crisaborole (dzina lazamalonda laku China: Sultanming, dzina lamalonda lachingerezi: Eucris a, Staquis) lidavomerezedwa, mwina kwa ana ndi akulu azaka za miyezi 3 ndi okalamba atopic dermatitis odwala.

Crisaborole ndi molekyu yaing'ono, yopanda mahomoni, yopanda anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor yopangidwa ndi Anacor. Mu Meyi 2016, Pfizer adapeza kampaniyo $ 5.2 biliyoni ndipo adapeza mankhwalawa. Mu Disembala chaka chomwecho, Crisaborole idavomerezedwa ndi FDA kuti igulitse, kukhala mankhwala oyamba aatopic dermatitis ovomerezeka m'zaka 10, komanso mankhwala oyamba akunja osagwiritsa ntchito steroidal oletsa khungu PDE4.

Crisaborole Inhibitors monga mankhwala atsopano, kwenikweni, mawonekedwe a mlingo wapakamwa akhala akugwiritsidwa ntchito kwa psoriasis ndi nyamakazi ya psoriatic, zotsatira zake zazikulu ndizosautsa m'mimba, palibe tsinde lina lapadera.

Crisaborole monga mankhwala apakhungu, ochepetsedwa pang'ono kudzera pakhungu, kuthekera kwapambuyo kwa vuto la m'mimba kumachepetsedwanso kukhala otsika kwambiri.

Zotsatira zake, Crisaborole mwadzidzidzi adakhala "chiyembekezo cha mudzi wonse" kuyambira zaka 15, madokotala ndi makolo akhala akufunitsitsa kukhala ndi chitetezo, chogwira ntchito komanso chogwiritsa ntchito nthawi yayitali mankhwala apakhungu ndi yayitali kwambiri.

Kodi mankhwalawa ndi Crisaborole amagwira ntchito bwanji?

Mu 2016, maphunziro awiri a chipatala a Phase III adabweretsa nkhani zosangalatsa kwambiri, Crisaborole, mafuta odzola a phosphodiesterase-4 (PDE4) inhibitors, kwa odwala atopic dermatitis a zaka zapakati pa 2 (ana ndi akuluakulu), adapeza zotsatira zabwino zachipatala.